Palatin Technologies Inc. (PTN) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, PTN scores 35 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC of -35%; FCF yield of 0%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10/20 (beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). The two weakest pillars, cash generation and institutional flow, are the ones an investor would weigh most heavily. A negative ROIC and zero FCF yield indicate the business is not currently generating returns on capital or free cash flow per the source data. The lowest flow score indicates limited institutional support in the source data. The balance sheet pillar is middling rather than distressed, with a Piotroski F of 1/9 signaling weak fundamental quality. For a prospective investor, this profile implies that any upside would have to come from a change in the cash-generation trajectory or from catalysts outside the current financials, while downside risk is elevated given the weak balance-sheet and flow readings.

Per the SEC financials, operating income was negative in each reported period, and FCF was negative in each period. Net income was negative in FY 2025 but positive in FY 2024 and FY 2023, a divergence the source data does not explain. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 1/9, and Debt/Equity is 0.5. Cash of $14.5M is reported for FY 2025, with debt in that period listed as N/A.

Recent items in the news feed are all tagged to PTN. Five are marked YELLOW (market wire) and one is marked GREEN (catalyst). The feed includes a debelegger.nl report, a Yahoo Finance UK seasonal returns chart, an Investing.com piece framing PTN as a possible fit for big pharma's obesity pipeline shopping beyond GLP-1s, a Kalkine stock profile, a MarketBeat note on the Q1 2027 earnings date and estimates, and a report noting shares ticking up 1.42% to $5.00 against near-term resistance. The GREEN-flagged item is the resistance-related report. The Investing.com headline is the only one that points to a specific strategic theme, but the feed does not confirm any transaction, partnership, or pipeline event. Risk watch items include the absence of any verified pipeline or revenue catalyst in the source data and the negative operating cash flow across all reported periods. Per the Butterfly Supply-Chain Graph, the supply chain is "NONE," with no butterfly links or proprietary signals recorded.

Per the Butterfly Supply-Chain Graph, there are no upstream or downstream links, no sector correlation mapping, and no proprietary signals recorded for PTN. As a result, the source data does not identify dependencies on suppliers, partners, or customers, and does not establish 2nd-order bottlenecks. The stock's sector placement (Health Care, Biotechnology: Pharmaceutical Preparations) is the only structural context available. Investors should watch for whether any pharma-sector developments referenced in news coverage translate into concrete counterparty relationships, though the source data cannot confirm this.

• What products or pipeline assets generate the reported revenue, and what is the current commercial or development status of each?
• What explains the swing from positive net income in FY 2024 and FY 2023 to a net loss in FY 2025, and is the FY 2025 loss driven by operating or non-operating items?
• What is the company's total debt and cash position in periods beyond FY 2025, given debt is N/A in the reported financials?
• Which catalysts, if any, are scheduled in the near term, and do they carry verifiable financing or partnership terms?
• What is the company's cash runway given negative FCF of -$21.3M in FY 2025 against cash of $14.5M?